预约演示
Endo's Par Pharma recalls one batch of its Remodulin generic over particulate concerns
2024-03-13
上市批准专利侵权优先审批生物类似药
The recalled lot of treprostinil injection was distributed in 2022 and expires next month.
Endo’s Par Pharmaceutreprostinilking one lot of its treprostinil injection from the U.S. market over concerns that silicone particles could be in vials of the drug.
EndobatPar Pharmaceuticaly arterial hypertension (PAtreprostinilres next month and has been on the shelves since 2022 after it was distributed to wholesalers and hospitals from June to October of that year, the company said in a press release.
While Par has notpulmonary arterial hypertension (PAH)events stemming from use of the recalled med, the consequences of particulate matter in an injectable could be dire. The impacts could range from irritation or swelling at the injection site to a stroke or even death if the particles reach the blood vessels and move to other organs.
The company is issuing written notifications to customers who received the batch plus sorting out the return of the existing inventory.
Treprostinil for injection is a generic to United Therapeutics’ Remodulin, which has been marketed for over 20 years.
Treprostinilprostacyclin vasodilator, is apUnited TherapeuticsmpRemodulinAH when used with exercise; it's also approved for patients who need to transition from tried and true PAH med epoprostenol. Remodulin is formulated for subcutaneous or intravenous infusion.
Meanwhile, iprostacyclin vasodilatormonth for U.S. drug recalls. A few dPAH ago, the FDA disclosed a recall of more than 55,000 bottles of Sun Pharma's gout treatment febuxostaPAHepoprostenolRemodulin
As for Par, its parent company Endo recently agreed to pay a bankruptcy settlement woFDA up to $464.9 million to the federal government aftSun Pharmatmegoutf Justice ifebuxostaton into its previous marketing of opioid painkiller Opana ER.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。